Please refer to our investors presentation for the quarter ended 30.06.2026

AI summary - Q1 FY27 revenue grew 22.1% y-y to Rs. 43.8 Cr; EBITDA rose 49.4% to Rs. 20.8 Cr; PAT increased 22.1% to Rs. 11.1 Cr - EBITDA margin improved 867 bps y-y to 47.5% due to economies of scale - Acquisitions of MicroBiopharm Japan and Sanofi brands to expand global reach and product portfolio; MicroBiopharm deal (~INR 1,300 Cr) expected to close Q2 FY27 - New fermentation facility completed; hybrid 18 MW wind-solar power plant underway to reduce costs and carbon footprint - FY26 revenue Rs. 165.8 Cr (+9.96% y-y); PAT Rs. 46.7 Cr (-4.29% y-y) with margin pressure - Focus on R&D, forward integration into API production, and capacity expansion - ESG initiatives include renewable power for captive consumption supporting margin stability